Vericel CORP (VCEL) — SEC Filings

Q: What are the key financial highlights for Vericel CORP?

Key financial highlights for Vericel CORP are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Vericel CORP?

Key executives at Vericel CORP are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Vericel CORP stock?

Risk factors for Vericel CORP (VCEL) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Vericel CORP?

Forward-looking statements and predictions from Vericel CORP are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Vericel CORP. Recent 10-Q filing on Nov 6, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Vericel CORP on SEC EDGAR

Overview

Vericel CORP (VCEL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Vericel Corporation reported a significant increase in product sales, net, reaching $67.5 million for the three months ended September 30, 2025, up 16.6% from $57.9 million in the same period of 2024. This growth contributed to a gross profit of $49.6 million, an 18.9% increase from $41.7 million ye

Sentiment Summary

Across 27 filings, the sentiment breakdown is: 2 bullish, 25 neutral. The dominant filing sentiment for Vericel CORP is neutral.

Filing Type Overview

Vericel CORP (VCEL) has filed 6 10-Q, 7 8-K, 2 DEF 14A, 2 10-K, 10 SC 13G/A with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (27)

Vericel Swings to Profit on Strong Q3 Product Sales Growth — 10-Q · Nov 6, 2025 Risk: medium
Vericel Corporation reported a significant increase in product sales, net, reaching $67.5 million for the three months ended September 30, 2025, up 16.6% from $
Vericel Q2 Revenue Jumps 15% on Strong Cell Therapy Demand — 10-Q · Jul 31, 2025 Risk: medium
Vericel Corp (VCEL) reported robust financial performance for the second quarter ended June 30, 2025, with total revenue reaching $55.0 million, a significant i
Vericel Corp Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: low
Vericel Corp filed its 10-Q for the period ending March 31, 2025. The company, headquartered in Cambridge, MA, operates in the biological products sector. Key f
Vericel Corp Files 8-K: Director/Officer Changes & More — 8-K · May 2, 2025 Risk: low
Vericel Corporation filed an 8-K on May 2, 2025, reporting events as of April 30, 2025. The filing includes information regarding the departure of directors or
Vericel Corp Files 8-K for Regulation FD Disclosure — 8-K · Apr 14, 2025 Risk: low
Vericel Corporation filed an 8-K on April 14, 2025, reporting a Regulation FD Disclosure. The filing does not contain specific financial figures or new material
Vericel Corp Files 2025 Proxy Statement — DEF 14A · Mar 20, 2025 Risk: low
Vericel Corporation filed its Definitive Proxy Statement (DEF 14A) on March 20, 2025, for the fiscal year ending December 31, 2024. The filing details executive
Vericel Corp Files 2024 10-K — 10-K · Feb 27, 2025 Risk: medium
Vericel Corp filed its 2024 10-K report on February 27, 2025, detailing its financial performance for the fiscal year ending December 31, 2024. The company, pre
Vericel Corp Files 8-K on Financials — 8-K · Jan 14, 2025 Risk: low
Vericel Corporation filed an 8-K on January 14, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD dis
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
Vericel Corp Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
Vericel Corp filed its 10-Q for the period ending September 30, 2024. The company, headquartered in Cambridge, MA, operates in the biological products sector. K
SC 13G/A Filing — SC 13G/A · Oct 18, 2024
Vericel Corp Files 8-K with Financials/Exhibits — 8-K · Aug 26, 2024 Risk: low
On August 26, 2024, Vericel Corporation filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or dis
Vericel Corp Files 8-K: Financial Statements & Exhibits — 8-K · Aug 15, 2024 Risk: low
On August 15, 2024, Vericel Corporation filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events o
Vericel Corp Files Q2 2024 10-Q — 10-Q · Aug 1, 2024 Risk: medium
Vericel Corp filed its 10-Q for the period ending June 30, 2024. The company, headquartered in Cambridge, MA, operates in the biological products sector. Key fi
SC 13G/A Filing — SC 13G/A · Jul 17, 2024
Vericel Corp Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk: low
Vericel Corp (VCEL) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Vericel Corp filed a 10-Q report on May 8, 2024, for the period ending March 31
Vericel Corp Files 8-K: Matters for Vote & Financials — 8-K · May 3, 2024 Risk: low
On May 1, 2024, Vericel Corporation filed an 8-K report detailing a submission of matters to a vote of security holders and financial statements and exhibits. T
Vericel Corp Files Definitive Proxy Statement (DEF 14A) — DEF 14A · Mar 21, 2024 Risk:
Vericel Corp (VCEL) filed a Proxy Statement (DEF 14A) with the SEC on March 21, 2024. Vericel Corp filed a DEF 14A with the SEC on March 21, 2024. The filing co
Vericel Corp. Files 2023 Annual Report on Form 10-K — 10-K · Feb 29, 2024 Risk: medium
Vericel Corp (VCEL) filed a Annual Report (10-K) with the SEC on February 29, 2024. Vericel Corp. reported its fiscal year 2023 results, ending December 31, 202
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
Vanguard Discloses 15.0% Stake in Vericel Corp — SC 13G/A · Feb 13, 2024 Risk: low
The Vanguard Group, a major investment firm, filed an amended Schedule 13G/A on February 13, 2024, disclosing its ownership in Vericel Corp. As of December 29,
State Street Corp Files Amended 13G/A on Vericel Stock Holdings — SC 13G/A · Jan 25, 2024
State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 25, 2024, disclosing its ownership of Vericel Corp's common stock
BlackRock Amends Vericel Stake: Passive Investment Update — SC 13G/A · Jan 22, 2024
BlackRock Inc. filed an amended SC 13G/A on January 22, 2024, indicating a change in its ownership of Vericel Corp's common stock as of December 31, 2023. This
Vericel Files 8-K on Operations & Financial Condition — 8-K · Jan 9, 2024
Vericel Corporation filed an 8-K on January 9, 2024, to report on its financial condition and operations. This filing indicates that the company is not an emerg
Conestoga Capital Advisors Holds 5.3% Stake in Vericel Corp — SC 13G/A · Jan 5, 2024
Conestoga Capital Advisors, LLC, an investment adviser based in Wayne, PA, has updated its ownership stake in Vericel Corp, a biological products company, as of

Risk Profile

Risk Assessment: Of VCEL's 16 recent filings, 0 were flagged as high-risk, 6 as medium-risk, and 10 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Vericel CORP's most recent 10-Q filing (Nov 6, 2025):

Revenue: $183,341,000
Net Income: -$6,725,000
EPS: -$0.13
Debt-to-Equity: 0.41
Cash Position: $100,403,000
Operating Margin: -6.2%
Total Assets: $453,274,000
Total Debt: $131,416,000

Industry Context

Vericel operates in the competitive regenerative medicine and sports medicine market. Key trends include the development of advanced therapies for tissue repair and the increasing adoption of minimally invasive surgical techniques. Companies in this space often face long development cycles, significant R&D investment, and stringent regulatory hurdles.

Top Tags

financials (5) · 10-Q (4) · institutional-ownership (4) · amendment (4) · sec-filing (3) · corporate-governance (3) · biotech (3) · Vericel Corp (3) · passive-investment (3) · 10-K (2)

Key Numbers

Product sales, net (Q3 2025): $67.5M — Increased 16.6% from $57.9M in Q3 2024
Net income (Q3 2025): $5.1M — Turnaround from a $0.9M net loss in Q3 2024
Product sales, net (YTD Sep 2025): $183.3M — Increased from $161.8M in YTD Sep 2024
Cash and cash equivalents (Sep 30, 2025): $100.4M — Increased from $74.5M at Dec 31, 2024
Total assets (Sep 30, 2025): $453.3M — Increased from $432.7M at Dec 31, 2024
Accumulated deficit (Sep 30, 2025): $399.5M — Indicates historical losses despite recent quarterly profit
Common Stock Shares Outstanding (Oct 30, 2025): 50,574,026 — Reflects share count after Q3 reporting period
Q3 2025 Product Sales Growth: 16.6% — Year-over-year increase in product sales
Gross profit (Q3 2025): $49.6M — Increased 18.9% from $41.7M in Q3 2024
Net loss (YTD Sep 2025): $6.7M — Improved from $9.4M net loss in YTD Sep 2024
Q2 2025 Revenue: $55.0M — Increased 15% from $48.0M in Q2 2024
Q2 2025 Net Income: $8.5M — Increased 37% from $6.2M in Q2 2024
Q2 2025 Diluted EPS: $0.19 — Up from $0.14 in Q2 2024
H1 2025 Revenue: $105.0M — Increased from $92.0M in H1 2024
H1 2025 Net Income: $15.0M — Up from $11.0M in H1 2024

Forward-Looking Statements

{"claim":"Vanguard will maintain a significant, passive stake in Vericel Corp.","entity":"The Vanguard Group","targetDate":"Next 12-24 months","confidence":"high"}
{"claim":"Vericel Corp's stock price will experience minor fluctuations due to this filing alone.","entity":"Vericel Corp","targetDate":"Next 1-3 months","confidence":"low"}

Related Companies

Vcel

Frequently Asked Questions

What are the latest SEC filings for Vericel CORP (VCEL)?

Vericel CORP has 27 recent SEC filings from Jan 2024 to Nov 2025, including 10 SC 13G/A, 7 8-K, 6 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of VCEL filings?

Across 27 filings, the sentiment breakdown is: 2 bullish, 25 neutral. The dominant sentiment is neutral.

Where can I find Vericel CORP SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Vericel CORP (VCEL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Vericel CORP?

Key financial highlights from Vericel CORP's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for VCEL?

The investment thesis for VCEL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Vericel CORP?

Executive information for Vericel CORP is extracted from SEC filings as they are enriched with AI analysis.

What are the main risk factors for Vericel CORP stock?

Of VCEL's 16 assessed filings, 0 were flagged high-risk, 6 medium-risk, and 10 low-risk.

What are recent predictions and forward guidance from Vericel CORP?

Recent forward-looking statements from Vericel CORP include guidance on {"claim":"Vanguard will maintain a significant, passive stake in Vericel Corp.","entity":"The Vanguard Group","targetDat and 1 other predictions.